Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 10 | 2016 | 1019 | 1.380 |
Why?
|
| Colorectal Neoplasms | 6 | 2024 | 512 | 1.350 |
Why?
|
| Sulfones | 4 | 2015 | 47 | 1.050 |
Why?
|
| MicroRNAs | 2 | 2024 | 518 | 0.970 |
Why?
|
| Colonoscopy | 4 | 2016 | 122 | 0.940 |
Why?
|
| Colonic Neoplasms | 7 | 2012 | 223 | 0.920 |
Why?
|
| Metabolic Diseases | 1 | 2026 | 40 | 0.920 |
Why?
|
| Fatty Liver | 1 | 2026 | 77 | 0.890 |
Why?
|
| Adenomatous Polyposis Coli | 7 | 2018 | 28 | 0.850 |
Why?
|
| Acrylonitrile | 2 | 2015 | 3 | 0.820 |
Why?
|
| Peritoneal Neoplasms | 3 | 2012 | 18 | 0.790 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2007 | 31 | 0.710 |
Why?
|
| Carcinoma | 2 | 2012 | 108 | 0.660 |
Why?
|
| Hedgehog Proteins | 2 | 2014 | 54 | 0.660 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 134 | 0.640 |
Why?
|
| Nitriles | 3 | 2012 | 81 | 0.610 |
Why?
|
| Health Status Disparities | 1 | 2026 | 719 | 0.590 |
Why?
|
| Apoptosis | 9 | 2015 | 1568 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 220 | 0.530 |
Why?
|
| Health Personnel | 1 | 2020 | 277 | 0.530 |
Why?
|
| Primary Health Care | 1 | 2020 | 380 | 0.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 968 | 0.500 |
Why?
|
| Adenoma | 5 | 2010 | 96 | 0.500 |
Why?
|
| Microfilament Proteins | 2 | 2014 | 72 | 0.490 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 449 | 0.490 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 4 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 3 | 2007 | 306 | 0.470 |
Why?
|
| Ovarian Neoplasms | 3 | 2015 | 415 | 0.460 |
Why?
|
| Rectal Diseases | 2 | 2005 | 4 | 0.460 |
Why?
|
| Receptors, Death Domain | 2 | 2011 | 2 | 0.430 |
Why?
|
| Follow-Up Studies | 6 | 2026 | 1067 | 0.430 |
Why?
|
| Pancreatic Neoplasms | 2 | 2015 | 218 | 0.430 |
Why?
|
| Humans | 33 | 2026 | 43102 | 0.420 |
Why?
|
| Peutz-Jeghers Syndrome | 2 | 2011 | 2 | 0.420 |
Why?
|
| Drug Design | 1 | 2015 | 186 | 0.400 |
Why?
|
| Neoplasms | 4 | 2012 | 1377 | 0.370 |
Why?
|
| Female | 18 | 2026 | 24698 | 0.350 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2011 | 9 | 0.350 |
Why?
|
| Mass Screening | 1 | 2016 | 541 | 0.350 |
Why?
|
| Histones | 1 | 2012 | 197 | 0.330 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1070 | 0.310 |
Why?
|
| Mice | 10 | 2015 | 6644 | 0.310 |
Why?
|
| Middle Aged | 11 | 2026 | 12222 | 0.300 |
Why?
|
| Clinical Trials as Topic | 2 | 2011 | 259 | 0.300 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2026 | 163 | 0.290 |
Why?
|
| Hawaii | 3 | 2020 | 2011 | 0.280 |
Why?
|
| Down-Regulation | 3 | 2011 | 456 | 0.280 |
Why?
|
| Liver Neoplasms | 2 | 2026 | 224 | 0.280 |
Why?
|
| Family | 2 | 2010 | 195 | 0.270 |
Why?
|
| Mice, Nude | 5 | 2012 | 408 | 0.270 |
Why?
|
| Male | 14 | 2026 | 23409 | 0.260 |
Why?
|
| Gastrostomy | 1 | 2007 | 8 | 0.260 |
Why?
|
| Foreign Bodies | 1 | 2007 | 6 | 0.260 |
Why?
|
| Aged | 7 | 2026 | 8214 | 0.260 |
Why?
|
| Gene Deletion | 2 | 2010 | 168 | 0.260 |
Why?
|
| Enteral Nutrition | 1 | 2007 | 17 | 0.260 |
Why?
|
| Deglutition Disorders | 1 | 2007 | 25 | 0.250 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2007 | 62 | 0.250 |
Why?
|
| Animals | 12 | 2015 | 16992 | 0.250 |
Why?
|
| Malnutrition | 1 | 2006 | 44 | 0.240 |
Why?
|
| Cell Proliferation | 5 | 2015 | 1455 | 0.230 |
Why?
|
| Integrin alpha5beta1 | 1 | 2005 | 6 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 734 | 0.230 |
Why?
|
| Colonic Diseases | 1 | 2004 | 11 | 0.220 |
Why?
|
| Genes, APC | 3 | 2016 | 15 | 0.220 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2676 | 0.220 |
Why?
|
| Caco-2 Cells | 3 | 2012 | 64 | 0.210 |
Why?
|
| Sulindac | 3 | 2018 | 9 | 0.210 |
Why?
|
| Feces | 1 | 2024 | 132 | 0.200 |
Why?
|
| HT29 Cells | 2 | 2015 | 60 | 0.200 |
Why?
|
| Cell Adhesion | 3 | 2011 | 238 | 0.200 |
Why?
|
| Organic Chemicals | 1 | 2002 | 36 | 0.190 |
Why?
|
| Signal Transduction | 6 | 2014 | 2157 | 0.190 |
Why?
|
| Adult | 10 | 2026 | 13872 | 0.190 |
Why?
|
| Anti-Infective Agents | 1 | 2002 | 75 | 0.180 |
Why?
|
| United States | 3 | 2026 | 5205 | 0.170 |
Why?
|
| Retrospective Studies | 4 | 2016 | 2544 | 0.170 |
Why?
|
| RNA, Messenger | 3 | 2014 | 1271 | 0.160 |
Why?
|
| Neoplasm Transplantation | 3 | 2012 | 129 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2002 | 358 | 0.160 |
Why?
|
| Prognosis | 2 | 2020 | 861 | 0.160 |
Why?
|
| Japan | 1 | 2020 | 348 | 0.160 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 506 | 0.160 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 67 | 0.150 |
Why?
|
| Neoplasm Seeding | 2 | 2013 | 5 | 0.150 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 138 | 0.150 |
Why?
|
| Disease Progression | 2 | 2020 | 667 | 0.140 |
Why?
|
| Cell Division | 2 | 2012 | 311 | 0.140 |
Why?
|
| Cell Differentiation | 2 | 2014 | 638 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1285 | 0.130 |
Why?
|
| Caspases | 2 | 2009 | 148 | 0.120 |
Why?
|
| Integrases | 1 | 2014 | 28 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 114 | 0.110 |
Why?
|
| Transfection | 2 | 2006 | 532 | 0.110 |
Why?
|
| Cell Nucleus | 3 | 2012 | 383 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1124 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2013 | 34 | 0.100 |
Why?
|
| Liver Diseases | 1 | 2013 | 34 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2013 | 37 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 652 | 0.100 |
Why?
|
| Molecular Structure | 1 | 2015 | 570 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2010 | 2853 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2014 | 883 | 0.090 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 41 | 0.090 |
Why?
|
| Peritoneum | 1 | 2012 | 9 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 154 | 0.090 |
Why?
|
| Risk Factors | 4 | 2013 | 3994 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2012 | 109 | 0.090 |
Why?
|
| Phosphorylation | 2 | 2005 | 986 | 0.090 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1035 | 0.090 |
Why?
|
| Ovary | 1 | 2012 | 113 | 0.090 |
Why?
|
| Epithelium | 1 | 2011 | 78 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2010 | 9 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 1621 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2010 | 66 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 526 | 0.080 |
Why?
|
| Porifera | 1 | 2009 | 16 | 0.080 |
Why?
|
| Alkaloids | 1 | 2009 | 46 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 436 | 0.070 |
Why?
|
| Imidazoles | 1 | 2009 | 142 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 237 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2008 | 224 | 0.070 |
Why?
|
| Age Distribution | 1 | 2008 | 249 | 0.070 |
Why?
|
| Genetic Testing | 2 | 2005 | 91 | 0.060 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2006 | 1 | 0.060 |
Why?
|
| Gastrointestinal Contents | 1 | 2006 | 2 | 0.060 |
Why?
|
| Enterocytes | 1 | 2006 | 4 | 0.060 |
Why?
|
| Microvilli | 1 | 2006 | 9 | 0.060 |
Why?
|
| TCF Transcription Factors | 1 | 2006 | 17 | 0.060 |
Why?
|
| Rats | 1 | 2014 | 3735 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 34 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2006 | 39 | 0.060 |
Why?
|
| Macular Degeneration | 1 | 2007 | 31 | 0.060 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2006 | 20 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 183 | 0.060 |
Why?
|
| Intestines | 1 | 2006 | 71 | 0.060 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2006 | 19 | 0.060 |
Why?
|
| Mitochondria | 1 | 2010 | 523 | 0.060 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2005 | 2 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 200 | 0.060 |
Why?
|
| Biotinylation | 1 | 2005 | 12 | 0.060 |
Why?
|
| Agar | 1 | 2005 | 9 | 0.060 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2005 | 31 | 0.060 |
Why?
|
| Fissure in Ano | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hemorrhoids | 1 | 2004 | 1 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 508 | 0.060 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2004 | 2 | 0.060 |
Why?
|
| Intestinal Polyps | 1 | 2004 | 4 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2005 | 150 | 0.060 |
Why?
|
| Diverticulum, Colon | 1 | 2004 | 3 | 0.060 |
Why?
|
| Angiodysplasia | 1 | 2004 | 3 | 0.060 |
Why?
|
| Ulcer | 1 | 2004 | 6 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 127 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2005 | 181 | 0.050 |
Why?
|
| Medical Records | 1 | 2004 | 48 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2005 | 154 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 186 | 0.050 |
Why?
|
| Lysosomes | 1 | 2005 | 86 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 665 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 209 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 131 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2004 | 9 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 70 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 423 | 0.050 |
Why?
|
| Colitis | 1 | 2004 | 71 | 0.050 |
Why?
|
| Introns | 1 | 2004 | 79 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2004 | 81 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 1612 | 0.050 |
Why?
|
| Abdominal Neoplasms | 1 | 2002 | 3 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 139 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2002 | 98 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 403 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 116 | 0.050 |
Why?
|
| Jews | 1 | 2002 | 6 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2003 | 192 | 0.050 |
Why?
|
| Adenomatous Polyps | 1 | 2002 | 13 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 592 | 0.050 |
Why?
|
| Age Factors | 1 | 2004 | 1154 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 1723 | 0.040 |
Why?
|
| Time Factors | 1 | 2005 | 1857 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2018 | 1604 | 0.040 |
Why?
|
| Phenotype | 3 | 2010 | 780 | 0.040 |
Why?
|
| Utah | 2 | 2010 | 10 | 0.040 |
Why?
|
| Pedigree | 2 | 2010 | 94 | 0.030 |
Why?
|
| Colectomy | 2 | 2004 | 24 | 0.030 |
Why?
|
| Needles | 1 | 2013 | 10 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 355 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Adamantane | 1 | 2010 | 10 | 0.020 |
Why?
|
| Cinnamates | 1 | 2010 | 7 | 0.020 |
Why?
|
| Cell Respiration | 1 | 2010 | 35 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2010 | 48 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 199 | 0.020 |
Why?
|
| Retinoids | 1 | 2010 | 25 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 103 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 48 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2010 | 150 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 197 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 38 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 80 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 152 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 296 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 157 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 152 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2010 | 281 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 346 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2006 | 12 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 532 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2006 | 24 | 0.020 |
Why?
|
| Back Pain | 1 | 2006 | 32 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1082 | 0.020 |
Why?
|
| DNA Glycosylases | 1 | 2005 | 17 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 245 | 0.010 |
Why?
|
| Endoscopy, Digestive System | 1 | 2004 | 7 | 0.010 |
Why?
|
| Rectum | 1 | 2004 | 27 | 0.010 |
Why?
|
| Physical Examination | 1 | 2004 | 45 | 0.010 |
Why?
|
| Family Health | 1 | 2004 | 55 | 0.010 |
Why?
|
| Registries | 1 | 2006 | 437 | 0.010 |
Why?
|
| Leupeptins | 1 | 2003 | 12 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2003 | 22 | 0.010 |
Why?
|
| Adolescent | 2 | 2005 | 6081 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 368 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 75 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 69 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 64 | 0.010 |
Why?
|
| beta Catenin | 1 | 2003 | 78 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2003 | 116 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2003 | 227 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 455 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 611 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 983 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 458 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 1542 | 0.010 |
Why?
|
| Child | 1 | 2005 | 3443 | 0.010 |
Why?
|